Newly Diagnosed Acute Myeloid Leukemia (AML)
Conditions
Brief summary
The purpose of this study is to describe the dose limiting toxicities (DLT) of SKLB1028 when combined with cytarabine/ daunorubicin remission induction in a 7+3 schedule. Safety and tolerability of SKLB1028 will also be evaluated. This study will also characterize the pharmacokinetics (PK) of SKLB1028 when given in combination with cytarabine/daunorubicin remission induction and high-dose cytarabine (HiDAC) consolidation therapy in newly diagnosed acute myeloid leukemia .
Interventions
DRUGSKLB1028 Dose Escalation
Drug :SKLB1028 ;Drug: Cytarabine ;Drug: Daunorubicin
Sponsors
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Study design
Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 59 Years
Healthy volunteers
No
Inclusion criteria
1. Subject has a diagnosis of previously-untreated de novo acute myeloid leukemia (AML) \> 20% blasts in the bone marrow according to WHO classification (2016) documented prior to enrollment.; 2. Age ≥ 18 and \< 60 years; 3. Subjects who are positive for FLT3 mutations by central laboratory; 4. Subject has an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2; 5. Subject must meet the following criteria as indicated on the clinical laboratory tests; 1. Serum aspartate aminotransf 2. Total serum bilirubin ≤ 2.5 x institutional ULN 3. Serum creatinine ≤ 3 x institutional ULN or an estimated glomerular filtration rate (eGFR) of \> 30 ml/min 6. Subject is suitable for oral administration of study drug.
Exclusion criteria
1. Confirmed diagnosis of acute promyelocytic leukemia (M3 /APL), or BCR-ABL positive leukemia (ie, blast crisis of chronic myelogenous leukemia); 2. Diagnosis of active malignancy other than AML; 3. AML secondary to radiotherapy or chemotherapy for other tumors; 4. AML with central nervous system involvement; 5. Refractory hypokalemia or hypomagnesemia that is not easily corrected by symptomatic treatment and that occurs repeatedly in the past; 6. Current clinically significant graft-ve 7. Previous history of other malignancies. 8. Patients with clinically significant coagulation abnormalities, such as disseminated intravascular coagulation (DIC), hemophilia A, hemophilia B, and von Willebrand disease; 9. Major surgery of major organs has been performed before entering the study (for the definition of major surgery, refer to Grade 3 and 4 surgery specified in Management Measures for Clinical Application of Medical Technology, or the patient has not yet fully recovered from 10. Subject has received prior therapy for AML with the following exceptions: a. emergency leukapheresis; b. emergency treatment with hydroxyurea ;c. growth factor or cytokine support; d. steroid for anaphylaxis or transfusion reaction;
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of participants with dose limiting toxicities (DLTs) | up to Day42 | A DLT is defined as any Grade ≥ 3 non-hematologic or extramedullary toxicity that occur during the DLT assessment period, and that is considered to be possibly, probably, or definitely related to onsolidation therapies including the study drugs. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| CR rate after the induction therapy | up to 3months | CR is defined as a morphologically leukemia-free state at the post-baseline visit, having a neutrophil count of ≥ 1,000/mm\^3 and platelet count of ≥ 100,000/mm\^3, bone marrow blasts \< 5%. There must be no evidence of Auer rods and no evidence of extramedullary leukemia. |
| Duration of remission | up to 24months | Duration of remission included duration of composite complete remission (CRc), duration of complete remission (CR)/ complete remission with partial hematologic recovery (CRh), duration of CRh, duration of CR and duration of response (CRc + partial remission (PR). |
| Overall Survival | up to 60months | OS was measured from the date of the first dose of treatment to the date of death from any cause or to the last date that the patient was known to be alive |
| Pharmacokinetics profile of SKLB1028 | Days 8, 15, 18, and 21 for remission induction and Days 8, and 21 for consolidation and Days 1 for maintenance | Observed trough concentration (Ctrough) |
| Leukemia-free survival | up to 24months | The LFS was defined as the time from the date of first CR until the date of documented relapse (excluding relapse from PR) or death for participants who achieved CR (relapse date or death date - first CR disease assessment date + 1). |
| Rate of hematopoietic stem cell transplantation | up to 12months | Transplantation rate is defined as the percentage of participants undergoing hematopoietic stem cell transplant (HSCT). |
| Event-Free Survival | up to 24months | EFS was defined as the time from randomization until treatment failure (Composite complete remission (CRc) or partial remission (PR) were not reached within 4 cycles), relapse (excluding relapse after PR), or death from any cause, whichever occurs first. |
Countries
China
Contacts
Primary ContactLiu Ting, Chief doctor
Backup ContactWang Jianxiang, Chief doctor
Outcome results
None listed